Inactive Instrument

Immune Pharmaceuticals Inc Stock price Nasdaq

Equities

US45254C1018

Pharmaceuticals

End-of-day quote Nasdaq
- USD 0.00% Intraday chart for Immune Pharmaceuticals Inc
Managers TitleAgeSince
Chief Executive Officer 37 21-04-11
Director of Finance/CFO 37 21-04-12
Chief Tech/Sci/R&D Officer - 17-12-10
Members of the board TitleAgeSince
Director/Board Member 64 -
Director/Board Member 56 17-08-14
Director/Board Member 60 16-02-01
More insiders
Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The Company's oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
More about the company
  1. Stock
  2. Equities
  3. Stock Immune Pharmaceuticals, Inc.
  4. Stock Immune Pharmaceuticals Inc - Nasdaq